​

Amneal Pharmaceuticals (AMRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMRX Stock Forecast

Amneal Pharmaceuticals (AMRX) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $21.25, with a high of $25.00 and a low of $16.00. This represents a 24.63% increase from the last price of $17.05.

$5 $9 $13 $17 $21 $25 High: $25 Avg: $21.25 Low: $16 Last Closed Price: $17.05

AMRX Stock Rating

Amneal Pharmaceuticals stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (64.71%), 6 Hold (35.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 6 11 Strong Sell Sell Hold Buy Strong Buy

AMRX Price Target Upside V Benchmarks

TypeNameUpside
StockAmneal Pharmaceuticals24.63%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.14%

Price Target Trends

1M3M12M
# Anlaysts149
Avg Price Target$23.00$23.00$19.33
Last Closing Price$17.05$17.05$17.05
Upside/Downside34.90%34.90%13.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2632---5
Aug, 2622---4
Jul, 2622---4
Jun, 2623---5
May, 2623---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Leerink Partners$23.00$17.0534.90%34.90%
Aug 03, 2026UBS$25.00$18.3236.46%46.63%
Jul 31, 2026Goldman Sachs$21.00$18.5013.51%23.17%
Jul 15, 2026Ashwani VermaUBS$23.00$17.1034.50%34.90%
May 20, 2026Glen SantangeloBarclays$16.00$11.8135.48%-6.16%
Apr 17, 2026Ashwani VermaUBS$19.00$13.0945.15%11.44%
Mar 02, 2026Les SulewskiTruist Financial$17.00$13.4526.39%-0.29%
Jan 07, 2026Truist Financial$15.00$12.9915.47%-12.02%
Dec 08, 2025Barclays$15.00$11.8726.37%-12.02%
Mar 03, 2025Barclays$11.00$8.7625.57%-35.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 31, 2026Goldman SachsBuyBuyhold
Jul 15, 2026UBSBuyBuyhold
May 20, 2026BarclaysOverweightOverweighthold
Apr 17, 2026UBSBuyinitialise
Dec 08, 2025BarclaysOverweightOverweightinitialise
Mar 03, 2025BarclaysOverweightOverweighthold
Nov 11, 2024Piper SandlerOverweightOverweighthold
Aug 13, 2024BarclaysOverweightOverweighthold
Aug 08, 2022Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-0.86$-0.48$-0.38$0.23-
Avg Forecast$0.70$0.57$0.61$0.70-
High Forecast$0.84$0.58$0.62$0.79-
Low Forecast$0.55$0.56$0.60$0.58-
Surprise %-222.86%-184.21%-162.30%-67.14%-

Revenue Forecast

$2B $2B $2B $3B $3B $4B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$2.21B$2.39B$2.79B$3.02B-
Avg Forecast$2.23B$2.41B$2.77B$2.90B$3.06B
High Forecast$2.68B$2.46B$2.83B$2.96B$3.13B
Low Forecast$1.79B$2.40B$2.73B$2.86B$3.02B
Surprise %-0.89%-0.68%0.86%4.10%-

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-129.99M$-83.99M$-116.89M$72.06M-
Avg Forecast$-131.13M$-83.99M$107.44M$120.65M-
High Forecast$-104.90M$-67.19M$109.20M$139.15M-
Low Forecast$-157.36M$-100.79M$105.68M$102.16M-
Surprise %-0.87%--208.79%-40.28%-

AMRX Forecast FAQ

Is Amneal Pharmaceuticals stock a buy?

Amneal Pharmaceuticals stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Amneal Pharmaceuticals is a favorable investment for most analysts.

What is Amneal Pharmaceuticals's price target?

Amneal Pharmaceuticals's price target, set by 17 Wall Street analysts, averages $21.25 over the next 12 months. The price target range spans from $16 at the low end to $25 at the high end, suggesting a potential 24.63% change from the previous closing price of $17.05.

How does Amneal Pharmaceuticals stock forecast compare to its benchmarks?

Amneal Pharmaceuticals's stock forecast shows a 24.63% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (26.14%).

What is the breakdown of analyst ratings for Amneal Pharmaceuticals over the past three months?

  • September 2026: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Amneal Pharmaceuticals’s EPS forecast?

Amneal Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0, marking a -100.00% decrease from the reported $0.23 in 2025..

What is Amneal Pharmaceuticals’s revenue forecast?

Amneal Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $3.06B, reflecting a 1.44% increase from the reported $3.02B in 2025.

What is Amneal Pharmaceuticals’s net income forecast?

Amneal Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $0, representing a -100.00% decrease from the reported $72.06M in 2025.